Vinge has advised Thermo Fisher Scientific Inc., (”Thermo Fisher”), the world leader in serving science, with annual revenue over $40 billion, in connection with its acquisition of Olink Holding AB (publ) (“Olink”).
Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all American Depositary Shares for $26.00 per common share in cash, representing $26.00 per American Depositary Share. The transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.
Olink is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala and the company’s shares are since 2021 traded on Nasdaq Global Market.
Vinge’s team mainly consisted of Jonas Bergström, Erik Sjöman, Samra Tesser, Linnéa Sellström and Anna Svensson (M&A and capital markets), Cecilia Möller Norstedt (litigation), Mattias Schömer and Emelie Svanberg (tax), Sam Seddigh, (employment), Daniel Wendelsson, Victoria Fredén and Hampus Peterson (FDI) and Malin Malm Waerme (IP).
